Critical evaluation of p53 as a prognostic marker in ovarian cancer

Expert Reviews in Molecular Medicine

Volumn 6, Issue 12, 2004, Pages 1-20

  Hall, Jacqueline ^a   Paul, Jim ^a   Brown, Robert ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Chemotherapy; Drug resistance; Ovarian cancer; p53; Predictive factor; Prognosis; Prognostic factor

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; PACLITAXEL; PLATINUM DERIVATIVE; PROTEIN P53; TAXANE DERIVATIVE; TAXOID;

APOPTOSIS; CANCER SURVIVAL; CELL CYCLE; CLINICAL TRIAL; CORRELATION ANALYSIS; DNA DAMAGE; DNA REPAIR; DRUG DOSE REGIMEN; GENE MUTATION; GENETIC CODE; GENETIC TRANSCRIPTION; HUMAN; IN VITRO STUDY; METHODOLOGY; OVARY CANCER; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; PUBLICATION; REVIEW; TREATMENT FAILURE; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; OVARIAN NEOPLASMS; PROGNOSIS; REVIEW LITERATURE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 15544390722     PISSN: 14623994     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1462399404007781     Document Type: Review

References (111)

1. Kastan, M.B. et al. (1991) Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51, 6304-6311,
2. Johnstone, R.W., Ruefli, A.A. and Lowe, S.W. (2002) Apoptosis: a link between cancer genetics and chemotherapy. Cell 108, 153-164,
3. Woods, D.B. and Vousden, K.H. (2001) Regulation of p53 function. Exp Cell Res 264, 56-66,
4. Hickman, E.S., Moroni, M.C. and Helin, K. (2002) The role of p53 and pRB in apoptosis and cancer. Curr Opin Genet Dev 12, 60-66,
5. Lowe, S.W. et al. (1994) p53 status and the efficacy of cancer therapy in vivo. Science 266, 807-810,
6. Wyllie, A.H. et al. (1994) Apoptosis in carcinogenesis: the role of p53. Cold Spring Harb Symp Quant Biol 59, 403-409,
7. Gallagher, W.M. and Brown, R. (1999) p53-oriented cancer therapies: current progress. Ann Oncol 10, 139-150,
8. Agarwal, R. and Kaye, S.B. (2003) Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 3, 502-516,
9. Perego, P. et al. (1996) Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res 56, 556-562,
10. Kaye, S.B. (2001) Future directions for the management of ovarian cancer. Eur J Cancer 37 Suppl 9, S19-23,
11. Bertelsen, K., Holund, B. and Andersen, E. (1993) Reproducibility and prognostic value of histologic type and grade in early epithelial ovarian cancer. Int J Gynecol Cancer 3, 72-79,
12. Thigpen, J.T. (2000) Chemotherapy for advanced ovarian cancer: overview of randomized trials. Semin Oncol 27, 11-16,
13. Aabo, K. et al. (1998) Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group. Br J Cancer 78, 1479-1487,
14. McGuire, W.P. et al. (1989) Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 111, 273-279,
15. Tattersall, M.N. (2002) Ovarian cancer chemotherapy: carboplatin as standard. Lancet 360, 500-501,
16. Tattersall, M.N. (2002) Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 360, 505-515,
17. McGuire, W.P. et al. (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334, 1-6,
18. Piccart, M.J. et al. (2000) Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 92, 699-708,
19. Pilotti, S. et al. (2002) ICON3 and chemotherapy for ovarian cancer. Lancet 360, 2087-2088; author reply 2088,
20. Wahl, A.F. et al. (1996) Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat Med 2, 72-79,
21. Gadducci, A. et al. (2000) p53 status is neither a predictive nor a prognostic variable in patients with advanced ovarian cancer treated with a paclitaxel-based regimen. Anticancer Res 20, 4793-4799,
22. Smith-Sorensen, B. et al. (1998) Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status. Br J Cancer 78, 375-381,
23. Lavarino, C. et al. (2000) p53 gene status and response to platinum/ paclitaxel-based chemotherapy in advanced ovarian carcinoma. J Clin Oncol 18, 3936-3945,
24. Costa, M.J. et al. (1999) Immunohistochemical markers of cell cycle control applied to ovarian and primary peritoneal surface epithelial neoplasms: p21(WAF1/CIP1) predicts survival and good response to platinin-based chemotherapy. Hum Pathol 30, 640-647,
25. Bosari, S. et al. (1993) p53 accumulation in ovarian carcinomas and its prognostic implications. Hum Pathol 24, 1175-1179,
26. Bar, J.K. et al. (2001) Expression and mutation of p53 in tumor effusion cells of patients with ovarian carcinoma: response to cisplatin-based chemotherapy. Tumour Biol 22, 83-91,
27. Kupryjanczyk, J. et al. (2003) Evaluation of clinical significance of TP53, BCL-2, BAX and MEK1 expression in 229 ovarian carcinomas treated with platinum-based regimen. Br J Cancer 88, 848-854,
28. Ayhan, A. and Tuncer, Z.S. (1998) p53 expression in ovarian carcinoma with regard to second-look findings. Eur J Gynaecol Oncol 19, 501-502,
29. Berker, B. et al. (2002) Prognostic value of p53 accumulation in epithelial ovarian carcinomas. Arch Gynecol Obstet 266, 205-209,
30. Mayr, D. et al. (2000) Immunohistochemical analysis of drug resistance-associated proteins in ovarian carcinomas. Pathol Res Pract 196, 469-475,
31. Hawes, D. et al. (2002) Correlation of p53 immunostaining in primary and residual ovarian cancer at the time of positive second-look laparotomy and its prognostic role: a Southwest Oncology Group ancillary study. Gynecol Oncol 87, 17-23,
32. Konstantinidou, A.E. et al. (2003) Reduced retinoblastoma gene protein to Ki-67 ratio is an adverse prognostic indicator for ovarian adenocarcinoma patients. Gynecol Oncol 88, 369-378,
33. Niwa, K. et al. (1994) Alteration of p53 gene in ovarian carcinoma: clinicopathological correlation and prognostic significance. Br J Cancer 70, 1191-1197,
34. Howells, R.E. et al. (2001) Glutathione S-transferase GSTM1 and GSTT1 genotypes in ovarian cancer: association with p53 expression and survival. Int J Gynecol Cancer 11, 107-112,
35. Okuda, T. et al. (2003) p53 mutations and overexpression affect prognosis of ovarian endometrioid cancer but not clear cell cancer. Gynecol Oncol 88, 318-325,
36. Herod, J.J. et al. (1996) The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. Cancer Res 56, 2178-2184,
37. Goff, B.A. et al. (1998) Immunophenotype of ovarian cancer as predictor of clinical outcome: evaluation at primary surgery and second-look procedure. Gynecol Oncol 70, 378-385,
38. Hengstler, J.G. et al. (1999) Activity of O(6)-methylguanine-DNA methyltransferase in relation to p53 status and therapeutic response in ovarian cancer. Int J Cancer 84, 388-395,
39. Marx, D. et al. (1998) Expression of the p53 tumour suppressor gene as a prognostic marker in platinum-treated patients with ovarian cancer. Eur J Cancer 34, 845-850,
40. Levesque, M.A. et al. (1995) Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer 75, 1327-1338,
41. Levesque, M.A. et al. (2000) Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy. Clin Cancer Res 6, 3260-3270,
42. Shahin, M.S. et al. (2000) The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma. Cancer 89, 2006-2017,
43. Nijman, H.W. et al. (1999) Influence of chemotherapy on the expression of p53, HER-2/neu and proliferation markers in ovarian cancer. Eur J Obstet Gynecol Reprod Biol 83, 201-206,
44. Rohlke, P. et al. (1997) p53 is a persistent and predictive marker in advanced ovarian carcinomas: multivariate analysis including comparison with Ki67 immunoreactivity. J Cancer Res Clin Oncol 123, 496-501,
45. van der Zee, A.G. et al. (1995) Value of P-glycoprotein, glutathione S-transferase pi, cerbB-2, and p53 as prognostic factors in ovarian carcinomas. J Clin Oncol 13, 70-78,
46. Klemi, P.J. et al. (1995) p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma. Cancer 76, 1201-1208,
47. Irie, T. et al. (2000) Alteration of a p53 gene status affects outcome of patients with recurrent ovarian cancer. Oncology 58, 237-241,
48. Petty, R. et al. (1998) Drug resistance in ovarian cancer - the role of p53. Pathol Oncol Res 4, 97-102,
49. McMenamin, M.E., O'Neill, A.J. and Gaffney, E.F. (1997) Extent of apoptosis in ovarian serous carcinoma: relation to mitotic and proliferative indices, p53 expression, and survival. Mol Pathol 50, 242-246,
50. Sheridan, E. et al. (1994) P53 mutation in a series of epithelial ovarian cancers from the U.K., and its prognostic significance. Eur J Cancer 30A, 1701-1704,
51. Dong, Y. et al. (1997) Reduced expression of retinoblastoma gene product (pRB) and high expression of p53 are associated with poor prognosis in ovarian cancer. Int J Cancer 74, 407-415,
52. Werness, B.A. et al. (1999) Prognostic significance of p53 and p21(waf1/ cip1) immunoreactivity in epithelial cancers of the ovary. Gynecol Oncol 75, 413-418,
53. Laframboise, S. et al. (2000) p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance. Cancer J 6, 302-308,
54. Ozalp, S.S. et al. (2000) Prognostic significance of deletion and over-expression of the p53 gene in epithelial ovarian cancer. Eur J Gynaecol Oncol 21, 282-286,
55. Skirnisdottir, I. et al. (2002) The prognostic importance of p53, bcl-2, and bax in early stage epithelial ovarian carcinoma treated with adjuvant chemotherapy. Int J Gynecol Cancer 12, 265-276,
56. Skomedal, H. et al. (1997) TP53 protein accumulation and gene mutation in relation to overexpression of MDM2 protein in ovarian borderline tumours and stage I carcinomas. J Pathol 181, 158-165,
57. Baekelandt, M. et al. (1999) Clinical significance of apoptosis-related factors p53, Mdm2, and Bcl-2 in advanced ovarian cancer. J Clin Oncol 17, 2061,
58. Schuyer, M. et al. (2001) Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2. Br J Cancer 85, 1359-1367,
59. Mano, Y. et al. (1999) Bcl-2 as a predictor of chemosensitivity and prognosis in primary epithelial ovarian cancer. Eur J Cancer 35, 1214-1219,
60. Righetti, S.C. et al. (1996) A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res 56, 689-693,
61. Wen, W.H. et al. (1999) p53 mutations and expression in ovarian cancers: correlation with overall survival. Int J Gynecol Pathol 18, 29-41,
62. Silvestrini, R. et al. (1998) The clinical predictivity of biomarkers of stage III-IV epithelial ovarian cancer in a prospective randomized treatment protocol. Cancer 82, 159-167,
63. Di Leo, A. et al. (1995) An I.T.M.O. group study on second-line treatment in advanced epithelial ovarian cancer: an attempt to identify clinical and biological factors determining prognosis. Eur J Cancer 31A, 2248-2254,
64. Hartmann, L.C. et al. (1994) Prognostic significance of p53 immunostaining in epithelial ovarian cancer. J Clin Oncol 12, 64-69,
65. Sakai, K. et al. (1999) Comparison of p53, Ki-67, and CD44v6 expression between primary and matched metastatic lesions in ovarian cancer. Gynecol Oncol 72, 360-366,
66. Anttila, M.A. et al. (1999) p21/WAF1 expression as related to p53, cell proliferation and prognosis in epithelial ovarian cancer. Br J Cancer 79, 1870-1878,
67. Anttila, M.A. et al. (1999) The prognostic significance of p53 expression quantitated by computerized image analysis in epithelial ovarian cancer. Int J Gynecol Pathol 18, 42-51,
68. Daponte, A. et al. (1999) p53 as a prognostic factor for stage III serous adenocarcinoma of the ovary. Anticancer Res 19, 2387-2389,
69. Reles, A. et al. (2001) Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin Cancer Res 7, 2984-2997,
70. Reles, A. et al. (1996) Immunostaining of p53 protein in ovarian carcinoma: correlation with histopathological data and clinical outcome. J Cancer Res Clin Oncol 122, 489-494,
71. Sagarra, R.A. et al. (2002) P53 and Bcl-2 as prognostic predictors in epithelial ovarian cancer. Int J Gynecol Cancer 12, 720-727,
72. Diebold, J. et al. (1996) bcl-2 expression, p53 accumulation, and apoptosis in ovarian carcinomas. Am J Clin Pathol 105, 341-349,
73. Ariyoshi, K. et al. (2000) Prognostic factors in ovarian carcinosarcoma: a clinicopathological and immunohistochemical analysis of 23 cases. Histopathology 37, 427-436,
74. Marks, J.R. et al. (1991) Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res 51, 2979-2984,
75. Geisler, H.E. et al. (2001) p21 and p53 in ovarian carcinoma: their combined staining is more valuable than either alone. Cancer 92, 781-786,
76. Valverde, J.J. et al. (2001) Prognostic value of DNA quantification in early epithelial ovarian carcinoma. Obstet Gynecol 97, 409-416,
77. Henriksen, R. et al. (1994) p53 expression in epithelial ovarian neoplasms: relationship to clinical and pathological parameters, Ki-67 expression and flow cytometry. Gynecol Oncol 53, 301-306,
78. Ferrandina, G. et al. (1999) p53 overexpression is associated with cytoreduction and response to chemotherapy in ovarian cancer. Br J Cancer 81, 733-740,
79. Eltabbakh, G.H. et al. (1997) p53 overexpression is not an independent prognostic factor for patients with primary ovarian epithelial cancer. Cancer 80, 892-898,
80. Sengupta, P.S. et al. (2000) p53 and related proteins in epithelial ovarian cancer. Eur J Cancer 36, 2317-2328,
81. Schildkraut, J.M. et al. (2000) Prognostic factors in early-onset epithelial ovarian cancer: a population-based study. Obstet Gynecol 95, 119-127,
82. Fallows, S. et al. (2001) P53 mutation does not affect prognosis in ovarian epithelial malignancies. J Pathol 194, 68-75,
83. Kassim, S.K. et al. (1999) Increased bcl-2 expression is associated with primary resistance to chemotherapy in human epithelial ovarian cancer. Clin Biochem 32, 333-338,
84. Allan, L.A. et al. (1996) The significance of p53 mutation and over-expression in ovarian cancer prognosis. Int J Gynecol Cancer 6, 483-490
85. Geisler, J.P. et al. (1997) Quantification of p53 in epithelial ovarian cancer. Gynecol Oncol 66, 435-438,
86. Sarkar, F.H., Li, Y.W. and Crissman, J.D. (1993) A method for PCR sequencing of the p53 gene from a single 10-microns frozen or paraffin-embedded tissue section. Biotechniques 15, 36-38,
87. Flaman, J.M. et al. (1995) A simple p53 functional assay for screening cell lines, blood, and tumors. Proc Natl Acad Sci U S A 92, 3963-3967,
88. Meinhold-Heerlein, I. et al. (2001) Evaluation of methods to detect p53 mutations in ovarian cancer. Oncology 60, 176-188,
89. Detre, S., Saclani Jotti, G. and Dowsett, M. (1995) A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol 48, 876-878,
90. Kmet, L.M., Cook, L.S. and Magliocco, A.M. (2003) A review of p53 expression and mutation in human benign, low malignant potential, and invasive epithelial ovarian tumors. Cancer 97, 389-404,
91. Bergamaschi, D. et al. (2003) p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 3, 387-402,
92. Schmoor, C., Sauerbrei, W. and Schumacher, M. (2000) Sample size considerations for the evaluation of prognostic factors in survival analysis. Stat Med 19, 441-452,
93. Fleiss, J., Tytun, A. and Ury, H.K. (1980) A simple approximation for calculating sample sizes for comparing independent proportions. Biometrics 36, 343-346
94. Cannistra, S.A. (2000) When is a "prognostic factor" really prognostic? J Clin Oncol 18, 3745-3747,
95. Clark, T.G. et al. (2001) A prognostic model for ovarian cancer. Br J Cancer 85, 944-952,
96. Schwartz, D.R. et al. (2002) Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res 62, 4722-4729,
97. Glass, G.V. (1976) Primary, secondary and meta-analysis of research. Education Research 5, 3-8
98. Skilling, J.S. et al. (1996) An abundance of p53 null mutations in ovarian carcinoma. Oncogene 13, 117-123,
99. Thames, H.D. et al. (2002) Immunohistochemically detected p53 mutations in epithelial tumors and results of treatment with chemotherapy and radiotherapy. A treatment-specific overview of the clinical data. Strahlenther Onkol 178, 411-421,
100. Macaskill, P., Walter, S.D. and Irwig, L. (2001) A comparison of methods to detect publication bias in meta-analysis. Stat Med 20, 641-654,
101. Simon, R. and Altman, D.G. (1994) Statistical aspects of prognostic factor studies in oncology. Br J Cancer 69, 979-985,
102. Mazumdar, M. and Glassman, J.R. (2000) Categorizing a prognostic variable: review of methods, code for easy implementation and applications to decision-making about cancer treatments. Stat Med 19, 113-132,
103. Zhang, L. et al. (2003) Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348, 203-213,
104. Rustin, G.J. et al. (1996) Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol 14, 1545-1551,
105. Berker, B. et al. (2002) Prognostic significance of apoptotic index and bcl-2 and p53 expression in epithelial ovarian carcinoma. Eur J Gynaecol Oncol 23, 505-510,
106. Kuge, Y. et al. (2004) Feasibility of 99m Tc-annexin V for repetitive detection of apoptotic tumor response to chemotherapy: an experimental study using a rat tumor model. J Nucl Med 45, 309-312,
107. Yamasaki, F., Tokunaga, O. and Sugimori, H. (1997) Apoptotic index in ovarian carcinoma: correlation with clinicopathologic factors and prognosis. Gynecol Oncol 66, 439-448,
108. Thor, A.D. et al. (1992) Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst 84, 845-855,
109. Yamaguchi, A. et al. (1992) Expression of p53 protein in colorectal cancer and its relationship to short-term prognosis. Cancer 70, 2778-2784,
110. Quinlan, D.C. et al. (1992) Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res 52, 4828-4831,
111. Balmain, A., Gray, J. and Ponder, B. (2003) The genetics and genomics of cancer. Nat Genet 33 Suppl, 238-244,